| Lessons learned from the clinical development and market authorization of Glybera LM Bryant, DM Christopher, AR Giles, C Hinderer, JL Rodriguez, JB Smith, ... Human gene therapy Clinical development 24 (2), 55-64, 2013 | 270 | 2013 |
| Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma MK Panjwani, JB Smith, K Schutsky, J Gnanandarajah, CM O'connor, ... Molecular Therapy 24 (9), 1602-1614, 2016 | 127 | 2016 |
| B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look JB Smith, C Stashwick, DJ Powell Jr Gynecologic oncology 134 (1), 181-189, 2014 | 120 | 2014 |
| Tumor regression and delayed onset toxicity following B7-H4 CAR T cell therapy JB Smith, E Lanitis, D Dangaj, E Buza, M Poussin, C Stashwick, ... Molecular Therapy 24 (11), 1987-1999, 2016 | 57 | 2016 |
| Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor K Schutsky, DG Song, R Lynn, JB Smith, M Poussin, M Figini, Y Zhao, ... Oncotarget 6 (30), 28911, 2015 | 51 | 2015 |
| CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers J Datta, S Xu, C Rosemblit, JB Smith, JA Cintolo, DJ Powell Jr, ... Cancer immunology research 3 (5), 455-463, 2015 | 30 | 2015 |
| A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma DL Hermanson, BE Barnett, S Rengarajan, R Codde, X Wang, Y Tan, ... Blood 128 (22), 2127, 2016 | 29 | 2016 |
| piggyBacTM-produced CAR-T cells exhibit stem-cell memory phenotype BE Barnett, DL Hermanson, JB Smith, X Wang, Y Tan, CE Martin, ... Blood 128 (22), 2167, 2016 | 24 | 2016 |
| A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes E Lanitis, JB Smith, D Dangaj, S Flingai, M Poussin, S Xu, BJ Czerniecki, ... Human gene therapy 25 (8), 730-739, 2014 | 23 | 2014 |
| B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient … R Mathur, BE Barnett, D Hermanson, J He, Z Zhang, S Rengarajan, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 3068 …, 2017 | 8 | 2017 |
| Feasibility and safety of cCD20 RNA CAR-bearing T cell therapy for the treatment of canine B cell malignancies JB Smith, MK Panjwani, K Schutsky, J Gnanandarajah, S Calhoun, ... Journal for ImmunoTherapy of Cancer 3 (2), 1-1, 2015 | 6 | 2015 |
| Production of universal anti-Bcma CAR-T cells with reduced alloreactivity, but potent effector function for the treatment of multiple myeloma X Wang, BE Barnett, C Martin, D Hermanson, X Li, J Smith, J Wu, ... Blood 130, 503, 2017 | 5 | 2017 |
| PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic exhibits improved potency and durability D Hermanson, BE Barnett, S Rengarajan, R Codde, CE Martin, X Wang, ... Cancer Research 77 (13_Supplement), 3759-3759, 2017 | 4 | 2017 |
| 277 Development of a robust manufacturing process for AB-1015, an integrated circuit T cell (ICT) product, using targeted, CRISPR integration of transgenes by electroporation … A Chang, S Phillips, M Lee, E Huang, N Anand, H Ko, S Tran, L Rios, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 3 | 2022 |
| Abstract A071: PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ... Cancer Research 78 (16_Supplement), A071-A071, 2018 | 2 | 2018 |
| High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells. X Wang, X Li, B Barnett, C Martin, D Hermanson, J Smith, S Rengarajan, ... Journal of Clinical Oncology 35 (15_suppl), 3048-3048, 2017 | 2 | 2017 |
| Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor N Mason, DJ Powell, MK Panjwani, J Smith US Patent 11,116,795, 2021 | 1 | 2021 |
| P-BCMA-ALLO1-a nonviral, allogeneic anti-BCMA CAR-T therapy with potent antitumor function for the treatment of multiple myeloma M Richter, S Cranert, YN Tan, M Tong, C Domingo, E Argus, SA Ibitokou, ... J IMMUNOTHER CANCER 7, O7, 2019 | 1 | 2019 |
| PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model. JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ... CANCER RESEARCH 78 (16), 63-63, 2018 | 1 | 2018 |
| 301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC I Scarfo, L Lim, K Dang, M Chew, R Sudhakah, M Nguyen, S Mohanty, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
